Andrey Korshunov1, Regina Sycheva, Andrey Golanov. 1. Department of Neuropathology, NN Burdenko Neurosurgical Institute, Fadeeva str. 5, Moscow, 125047, Russia. akorshunov@nsi.ru
Abstract
PURPOSE: There is considerable morphologic overlap between various entities of high-grade gliomas, and, therefore, a further planning of their optimal treatment is a controversial issue. The aim of this study was molecular stratification of morphologically ambiguous high-grade gliomas composed from small cells. Fluorescence in situ hybridization (FISH) with commercially available probes was used for this purpose. EXPERIMENTAL DESIGN: We analyzed a set of 114 high-grade small-cell gliomas that were difficult to interpret diagnostically because of their distinct cytological origin. FISH assay with locus probes for EGFR, p16, PTEN, and 1p and 19q was done. RESULTS: Morphologically uniform high-grade gliomas composed of small cells varied greatly in terms of molecular features and clinical outcome. Four clinically relevant subsets of patients whose tumors showed distinctly different molecular profiles were identified as follows: (a) 13 patients whose tumors exhibited no discernable molecular alterations (5-year survival rate, 83%); (b) 20 patients whose tumors harbored either 1p/19q codeletion or isolated deletion of 19q unaccompanied by other molecular abnormalities (5-year survival rate, 59%); (c) 35 patients whose tumors showed p16 and/or PTEN deletions unaccompanied by EGFR amplification (5-year survival rate, 8%); and (d) 46 patients whose tumors harbored EGFR amplification (5-year survival rate, 0). CONCLUSIONS: The FISH method provides clinically useful information in the molecular analysis of morphologically ambiguous malignant small-cell gliomas that could potentially enhance the quality of patient care.
PURPOSE: There is considerable morphologic overlap between various entities of high-grade gliomas, and, therefore, a further planning of their optimal treatment is a controversial issue. The aim of this study was molecular stratification of morphologically ambiguous high-grade gliomas composed from small cells. Fluorescence in situ hybridization (FISH) with commercially available probes was used for this purpose. EXPERIMENTAL DESIGN: We analyzed a set of 114 high-grade small-cell gliomas that were difficult to interpret diagnostically because of their distinct cytological origin. FISH assay with locus probes for EGFR, p16, PTEN, and 1p and 19q was done. RESULTS: Morphologically uniform high-grade gliomas composed of small cells varied greatly in terms of molecular features and clinical outcome. Four clinically relevant subsets of patients whose tumors showed distinctly different molecular profiles were identified as follows: (a) 13 patients whose tumors exhibited no discernable molecular alterations (5-year survival rate, 83%); (b) 20 patients whose tumors harbored either 1p/19q codeletion or isolated deletion of 19q unaccompanied by other molecular abnormalities (5-year survival rate, 59%); (c) 35 patients whose tumors showed p16 and/or PTEN deletions unaccompanied by EGFR amplification (5-year survival rate, 8%); and (d) 46 patients whose tumors harbored EGFR amplification (5-year survival rate, 0). CONCLUSIONS: The FISH method provides clinically useful information in the molecular analysis of morphologically ambiguous malignant small-cell gliomas that could potentially enhance the quality of patient care.
Authors: Ana Luísa Vital; Maria Dolores Tabernero; Abel Castrillo; Olinda Rebelo; Hermínio Tão; Fernando Gomes; Ana Belen Nieto; Catarina Resende Oliveira; Maria Celeste Lopes; Alberto Orfao Journal: Neuro Oncol Date: 2010-05-18 Impact factor: 12.300
Authors: Dayane B Koshiyama; Patrícia Trevisan; Carla Graziadio; Rafael F M Rosa; Bibiana Cunegatto; Juliete Scholl; Valentina O Provenzi; Alexandre P de Sá; Fabiano P Soares; Maíra C Velho; Nelson de A P Filho; Ceres A Oliveira; Paulo R G Zen Journal: J Neurooncol Date: 2017-08-30 Impact factor: 4.130
Authors: Rajbir K Gill; Madeline F Vazquez; Arin Kramer; Megan Hames; Lijuan Zhang; Kerstin Heselmeyer-Haddad; Thomas Ried; Konstantin Shilo; Claudia Henschke; David Yankelevitz; Jin Jen Journal: Clin Cancer Res Date: 2008-11-15 Impact factor: 12.531
Authors: Ondrej Kalita; Miroslav Kala; Hana Svebisova; Jiri Ehrmann; Alice Hlobilkova; Radek Trojanec; Marian Hajduch; Michael Houdek Journal: J Neurooncol Date: 2008-06 Impact factor: 4.130
Authors: T Ettl; K Baader; C Stiegler; M Müller; A Agaimy; J Zenk; T Kühnel; M Gosau; K Zeitler; S Schwarz; G Brockhoff Journal: Br J Cancer Date: 2012-01-12 Impact factor: 7.640